Glia Nova Nyilvanosan Mukodo Reszvenytarsasag
BBUD:GLIA68.00
HUF
+6.00
(+9.68%)
ISIN
HU0000214358
Return %
Stock
S&P 500
1Y
-15.00
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
HUF
•
in mil. unless spec.Working Capital
HUF
•
in mil. unless spec.Growth Rates
HUF
•
in mil. unless spec.Semi-annual Revenue
HUF
•
in mil. unless spec.Semi-annual Earnings Per Share
HUF
•
in mil. unless spec.Semi-annual Dividends Per Share
HUF
•
in mil. unless spec.Company Description
- Sector
- Finance
- Industry
- Finance/Rental/Leasing
- Address
- Budapest Hungary
- IPO Date
- Apr 29, 2025
- Website
- glianova.hu
- Similar Companies
- Business
- Glia Nova Nyilvanosan Mukodo Reszvenytarsasag is a Hungary-based technology and software development company specializing in healthcare information technology, artificial intelligence-driven medical data solutions, and enterprise software engineering. Founded in 2008 and headquartered in Budapest, Hungary, the company develops and integrates advanced digital platforms for healthcare providers, clinical institutions, research organizations, and corporate clients across Hungary and the broader Central and Eastern European region. The company operates through specialized business divisions encompassing healthcare IT, custom application development, and technological infrastructure services. Its core products and services include: clinical workflow management and hospital information software; medical data processing and diagnostic support systems; telemedicine and remote patient monitoring platforms; artificial intelligence and machine learning analytics for healthcare and commercial data; bespoke enterprise resource planning and digital transformation software; cloud infrastructure design, migration, and database management; and IT consulting, cybersecurity advisory, systems integration, and ongoing software maintenance services. In recent corporate developments, Glia Nova Nyilvanosan Mukodo Reszvenytarsasag transitioned to a public limited company structure and completed its listing on the Budapest Stock Exchange under the ticker symbol GLIA. Over the past two years, the company has executed targeted capital increases to accelerate research and development in clinical artificial intelligence, entered into collaborative partnerships with academic medical centers and healthcare networks to expand diagnostic software validation, broadened its cloud-based software-as-a-service offerings, and restructured its operational units to support scalable market expansion and institutional commercialization across international markets.